TKM-PLK1

N/A

Report date: 2022/08/16 20:00:19

Base Information

Drug NameTKM-PLK1
Drug Alias NamePLK1-LNPTKM-080301PLK-1SNALPTKM-PLK1
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionPolo like kinase 1 inhibitorsRNA interference
TargetsPolo like kinase 1
Therapy Area/IndicationsNeoplasm MetastasisOvarian NeoplasmsPancreatic Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[6] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArbutus Biopharma CorpNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisOvarian NeoplasmsPancreatic Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksN/A